Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Chemotherapy with Local Treatments in Stage III-N3 NSCLC
NCT06908733Phase 2Not yet recruiting
- Sponsor
- Liaoning Medical Center
- Start
- Mar 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Liaoning Medical Center. Primary endpoint: 1-year Event-Free Survival Rate. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06908733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06908733.